What is the impact of the change in DDD of amoxicillin and amoxicillin combined with β-lactamase inhibitors on nationwide surveillance of antimicrobial use?

J Antimicrob Chemother. 2019 Oct 1;74(10):3119-3121. doi: 10.1093/jac/dkz305.

Yoshiki Kusama^{1

2}, Masahiro Ishikane^{1

3}, Chika Tanaka¹, Shinya Tsuzuki¹, Yuichi Muraki⁴, Norio Ohmagari^{1

2

3}

¹ AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
² Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
³ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
⁴ Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.

No abstract available

Publication types